China approves Daklinza/Sunvepra combo for HCV

Bristol-Myers Squibb Co. (NYSE:BMY) said China FDA approved Daklinza daclatasvir (BMS-790052) in combination with Sunvepra asunaprevir to treat

Read the full 182 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE